EP Patent

EP4233849A1 — Pharmaceutical composition comprising pomalidomide

Assigned to KRKA dd · Expires 2023-08-30 · 3y expired

What this patent protects

The invention pertains to pharmaceutical compositions and pharmaceutical dosage forms containing Pomalidomide, optionally in combination with one or more other active pharmaceutical substances, and low-substituted hydroxypropyl cellulose. The pharmaceutical compositions and pharm…

USPTO Abstract

The invention pertains to pharmaceutical compositions and pharmaceutical dosage forms containing Pomalidomide, optionally in combination with one or more other active pharmaceutical substances, and low-substituted hydroxypropyl cellulose. The pharmaceutical compositions and pharmaceutical dosage forms are physically and chemically stable and are easy to manufacture. The pharmaceutical compositions and pharmaceutical dosage are provided in a solid form suitable for oral administration. The invention further provides a methods for making the pharmaceutical compositions and pharmaceutical dosage forms.

Drugs covered by this patent

Patent Metadata

Patent number
EP4233849A1
Jurisdiction
EP
Classification
Expires
2023-08-30
Drug substance claim
No
Drug product claim
No
Assignee
KRKA dd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.